Table 1: Comparison of clinical, angiographic and laboratory features of TA patients at baseline and follow-up.
|
At Baseline |
Follow up |
|
Active |
Stable |
Active |
Stable |
| N |
15 |
17 |
4 |
28 |
| Median age in years (IQR) |
24.0(20.0-29.0) |
32.0(25.0-42.5) |
24.0(20.3-45.8) |
28.5(20.8-34.5) |
| Male/Female |
1/14 |
2/15 |
0/4 |
3/25 |
| Median disease duration prior to recruitment in months (IQR) |
18.0(6.0-36.0) |
24.0(12.0-54.0) |
9.5(5.0-16.3) |
6.5(3-10.75) |
| ITAS-2010 |
6.0(2.0-8.0) |
0.0(0.0-0.0) |
3.5(0.8-7.8) |
0(0.0-0.0) |
| ESR (mm/1st hr) |
36.5(14.0-70.8) |
20.0(13.5-43.0) |
34(15-35) |
20(12-39) |
| CRP (mg/L) |
4.5 (1.1-33.2) |
3.4(0.6-11.0) |
15.6(6.11-18.0) |
2.9 (0.73-12.3) |
| Angiographic assessment |
|
|
|
|
| Type1:2:3:4:5 (n) |
3: 0: 2: 2: 8 |
7: 0: 2: 3: 5 |
1: 0: 0: 0: 3 |
9: 0: 4: 5: 10 |
| Serum Cytokines levels(pg/ml) |
| IFN-γ** |
2.8(0-12.8) |
0(0-0) |
0(0-22.35) |
0(0-8.83) |
| IL-6* |
18.2(3.2-46.2) |
9.6(4.8-16.33) |
24.85(7.6-45.05) |
8.8(4.8-17.65) |
| IL-23* |
1.0(0.0-12.5) |
0.0(0.0-2.6) |
2.1(0-13.54) |
0(0-6.94) |
| IL-17* |
0.0(0.0-2.0) |
0.0(0.0-2.95) |
3.2(0-10.38) |
0(0-1.58) |
| IL-10* |
1.4(0.0-6.9) |
2.8(1.8-6.2) |
3.45(2.28-11.6) |
4.1(2.8-6.55) |
| TGF-β* |
169.1(98.9-235.1) |
206.3(78.9-249.1) |
203.3(101.7-242.6) |
173.1(96.6-237.9) |
**p <0.01. *P values for IL-6, IL-23, IL-17, IL-10 and TGF-β are 0.3447, 0.1548, 0.7693, 0.2285 and 0.8799 respectively for comparison between active vs. stable disease group.